Jacob Wohlstadter
Overview
Explore the profile of Jacob Wohlstadter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ripamonti E, Gisslen M, Hagberg L, Bathala P, Kale S, Stengelin M, et al.
J Neuroimmunol
. 2025 Feb;
400:578521.
PMID: 39914269
Background: A retrospective study was conducted in people with HIV (PWH) to explore potential cerebrospinal fluid (CSF) biomarkers linked to CSF neurofilament light levels (NfL), indicative of neuronal injury. Methods:...
2.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14508.
PMID: 39907496
Introduction: The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD...
3.
Cardenas E, Robertson J, Misaghian S, Brown J, Wang M, Stengelin M, et al.
Front Immunol
. 2024 Oct;
15:1434186.
PMID: 39430762
Background: IL-26 is a key mediator of pulmonary host defense given its abundant expression in human airways and its established antibacterial properties. Moreover, recent studies indicate that IL-26 can also...
4.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
medRxiv
. 2024 Sep;
PMID: 39228740
Background: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer's disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimer's Association Global...
5.
Ghorbani A, Chatanaka M, Avery L, Wang M, Brown J, Cohen R, et al.
Clin Proteomics
. 2024 Jun;
21(1):41.
PMID: 38879494
Background: Gliomas are aggressive malignant tumors, with poor prognosis. There is an unmet need for the discovery of new, non-invasive biomarkers for differential diagnosis, prognosis, and management of brain tumors....
6.
Chatanaka M, Avery L, Pasic M, Sithravadivel S, Rotstein D, Demos C, et al.
Clin Proteomics
. 2024 Apr;
21(1):28.
PMID: 38580905
Background: Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquaporin-4 (αAQP4) and myelin oligodendrocyte glycoprotein (αMOG). The...
7.
Kivisakk P, Fatima H, Cahoon D, Otieno B, Chacko L, Minooei F, et al.
Sci Rep
. 2024 Jan;
14(1):629.
PMID: 38182740
A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to detect amyloid pathology and...
8.
Chatanaka M, Avery L, Pasic M, Sithravadivel S, Rotstein D, Demos C, et al.
Res Sq
. 2023 Dec;
PMID: 38077014
Background: Certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) exhibit serum autoantibodies against aquaporin-4 (αAQP4) and myelin oligodendrocyte glycoprotein (αMOG). The...
9.
Campbell C, Padmanabhan N, Romero D, Joe J, Gebremeskel M, Manjula N, et al.
Sci Rep
. 2022 Apr;
12(1):6560.
PMID: 35449177
Convenient and widespread serology testing may alter the trajectory of the COVID-19 pandemic. This study seeks to leverage high-throughput, multiplexed serologic assays, which have been adopted as benchmarks for vaccine...